Parameter | ABC/3TC (n = 20) | TDF/FTC (n = 20) |
---|---|---|
Mean age (SD), years | 50 (11.9) | 46 (8.7) |
Male sex, n (%) | 11 (55.0) | 14 (70.0) |
Active smokers, n (%) | 6 (30.0) | 9 (45.0) |
Mean weight (SD), kg | 73.2 (12.1) | 74.9 (16.3) |
Mean BMI (SD), kg/m2 | 25.2 (2.1) | 25.0 (4.3) |
Mean systolic blood pressure (SD), mmHg | 133 (21.9) | 135 (15.1) |
Mean diastolic blood pressure (SD), mmHg | 85 (10.9) | 84 (9.4) |
Median total cholesterol (IQR), mmol/L | 5.7 (5.3-6.7) | 5.35 (4.8-6.0) |
Median LDL cholesterol (IQR), mmol/L | 3.8 (3.1-4.3) | 3.2 (2.6-4.0) |
Median HDL cholesterol (IQR), mmol/L | 1.3 (1.1-1.9) | 1.2 (1.0-1.7) |
Median triglyceride (IQR), mmol/L | 1.5 (1.2-2.0) | 1.4 (1.0-2.0) |
Mean fasting plasma glucose (SD), mmol/L | 5.4 (0.52) | 5.4 (0.38) |
Zidovudine/lamivudine at baseline, n (%) | 20 (100) | 20 (100) |
PI at baseline, n (%) | 6 (30.0) | 6 (30.0) |
Efavirenz at baseline, n (%) | 11 (55.0) | 9 (45.0) |
Nevirapine at baseline, n (%) | 3 (15.0) | 5 (25.0) |
Mean CD4+ cell count (SD), cells/mm2, | 567 (256) | 540 (206) |
Median duration of HAART exposure (IQR), months | 86.5 (54.5-125) | 106.5 (50.5-130) |
Median time since HIV-diagnosis (IQR), months | 127 (96.5-140.5) | 122 (89-179) |
Median Framingham score (IQR) | 3 (0-6) | 4 (1-7) |
Median estimated 10-year cardiovascular risk a.m. Framingham (IQR), % | 7 (3-10) | 6 (3-11) |